The 2025 MDF Conference was our largest and most international gathering to date. With more than 700 attendees from 34 US States and 10 countries, we were thrilled to welcome such a vibrant and engaged global community.

Dr. Samuel Carrell's scientific and clinical focus has been directed toward myotonic dystrophy since his PhD at the University of Rochester, where he studied DMPK reduction in mouse models. His work contributed to understanding the cardiac risks of DMPK reduction, supporting the therapeutic potential of antisense oligonucleotide therapies. Dr. Carrell also developed methods for measuring toxic CUG repeat RNA and investigating allele-selective targeting.

With over a decade of experience in DM1 research, Dr. Katrarzyna Taylor has advanced therapeutic strategies using antisense oligonucleotides, small compounds, and drug repositioning. She has developed expertise in molecular techniques, bioinformatics, and therapeutic screening.

This July, MDF is thrilled to host the 2025 Myotonic Dystrophy In Motion Awareness Month—a month-long celebration centered around the theme: Movement Matters.